Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
BridgeBio Pharma Inc (NASDAQ: BBIO) closed the day trading at $63.37 down -4.88% from the previous closing price of $66.62. In other words, the price has decreased by -$4.88 from its previous closing price. On the day, 4.84 million shares were traded. BBIO stock price reached its highest trading level at $67.75 during the session, while it also had its lowest trading level at $62.705.
Ratios:
For a better understanding of BBIO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.08 and its Current Ratio is at 5.19.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $66.
On July 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $70.Jefferies initiated its Buy rating on July 14, 2025, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 29 ’25 when Frank McCormick bought 198,359 shares for $66.58 per share.
MCCORMICK FRANK sold 1,641 shares of BBIO for $106,665 on Oct 27 ’25. The Director now owns 878,338 shares after completing the transaction at $65.00 per share. On Oct 27 ’25, another insider, Frank McCormick, who serves as the Director of the company, bought 1,641 shares for $65.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 12211957760 and an Enterprise Value of 13846560768. For the stock, the TTM Price-to-Sale (P/S) ratio is 51.79. Its current Enterprise Value per Revenue stands at 58.719 whereas that against EBITDA is -22.2.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.41, which has changed by 1.4870486 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $69.48, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 18.20%, while the 200-Day Moving Average is calculated to be 50.86%.
Shares Statistics:
Over the past 3-months, BBIO traded about 2.59M shares per day on average, while over the past 10 days, BBIO traded about 3269860 shares per day. A total of 191.16M shares are outstanding, with a floating share count of 162.32M. Insiders hold about 15.09% of the company’s shares, while institutions hold 89.18% stake in the company. Shares short for BBIO as of 1760486400 were 17353906 with a Short Ratio of 6.71, compared to 1757894400 on 19444136. Therefore, it implies a Short% of Shares Outstanding of 17353906 and a Short% of Float of 15.229999999999999.
Earnings Estimates
The dynamic stock of BridgeBio Pharma Inc (BBIO) is currently attracting attention from 3.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.58 and low estimates of -$0.59.
Analysts are recommending an EPS of between -$2.1 and -$3.46 for the fiscal current year, implying an average EPS of -$2.78. EPS for the following year is -$1.68, with 5.0 analysts recommending between -$0.97 and -$2.22.
Revenue Estimates
13 analysts predict $151.94M in revenue for. The current quarter. It ranges from a high estimate of $217.49M to a low estimate of $131.9M. As of. The current estimate, BridgeBio Pharma Inc’s year-ago sales were $5.88MFor the next quarter, 13 analysts are estimating revenue of $169.09M. There is a high estimate of $205.1M for the next quarter, whereas the lowest estimate is $141.8M.
A total of 16 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $565.39M, while the lowest revenue estimate was $456.4M, resulting in an average revenue estimate of $494.38M. In the same quarter a year ago, actual revenue was $221.9MBased on 17 analysts’ estimates, the company’s revenue will be $842M in the next fiscal year. The high estimate is $1.1B and the low estimate is $647M.
